Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 35.3%

Key Points

• Short interest in Coeptis Therapeutics Holdings, Inc. decreased by 35.3% in September, with a total of 41,200 shares sold short as of September 15th.
• Weiss Ratings has reaffirmed a "sell (e+)" rating on Coeptis Therapeutics, contributing to a consensus rating of "Sell" for the stock.
• As of the latest trading session, Coeptis Therapeutics' stock price rose 2.3%, trading at approximately $17.00 per share.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 41,200 shares, a decline of 35.3% from the August 31st total of 63,700 shares. Currently, 1.0% of the company's shares are sold short. Based on an average daily trading volume, of 54,500 shares, the days-to-cover ratio is presently 0.8 days. Based on an average daily trading volume, of 54,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.0% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Coeptis Therapeutics in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics has a consensus rating of "Sell".

Coeptis Therapeutics Stock Up 2.3%

NASDAQ COEP opened at $17.00 on Friday. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average of $13.28 and a two-hundred day moving average of $10.67. The firm has a market capitalization of $81.94 million, a price-to-earnings ratio of -2.93 and a beta of -0.49. Coeptis Therapeutics has a 52 week low of $2.31 and a 52 week high of $19.19.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share for the quarter. The firm had revenue of $0.20 million during the quarter.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.